US Drug Recall Register
Class II · Moderate risk Terminated Initiated Jan 29, 2014 (13 years ago)

Oxcarbazepine Tablets

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Failed Tablet Specifications: Broken Tablets Present.

What was recalled

Oxcarbazepine Tablets, 300 mg, 100 tablet bottles, Rx Only. Distributed by: Caraco Pharmaceutical Laboratories, Ltd., 1150 Elijiah McCoy Drive, Detroit, MI, 48202. Manufactured by: Sun Pharmaceutical Ind. Ltd., Acme Plaza, Andheri-Kurla Road, Andheri (East), Mumbai-400 059, India. NDC 62756-184-88, Rx only, 100 Tablets; Pharmacist: Dispense the Medication Guide provided separately to each patient. Each film-coated tablet contains 300 mg oxcarbazepine, USP, Usual Dosage: See package insert, Dispense in tight container (USP) tore at 25 C (77 F) excursions permitted.... Distributed by Caraco Pharmaceuticals Detroit, MI....

Recalling firm
Caraco Pharmaceutical Laboratories Ltd.
NDC code
62756-184-88
Origin
NJ, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-1081-2014

What should you do? A recall doesn't always mean your specific bottle is affected - it often applies to certain lots only. Check the lot number on your package against the FDA notice, and talk to your pharmacist before stopping any medication.

Other East recalls

See all
Class II · Moderate risk Ongoing

Diovan

Reason Failed Dissolution Specifications

Novartis Pharmaceuticals Corporation NDC 0078-0359-34 D-0746-2026
Class II · Moderate risk Ongoing

Clindamycin Palmitate Hydrochloride for Oral Solution

Reason Presence of Foreign Substance: presence of particles and white flakes in the reconstituted bottles.

Heritage Pharmaceuticals Inc NDC 23155-603-51 D-0768-2026
Class II · Moderate risk Ongoing

Dicyclomine Hydrochloride Capsules

Reason shortfill; reports of empty capsules.

Aurobindo Pharma USA Inc NDC 59651-719-99 D-0733-2026
Class II · Moderate risk Ongoing

Rising

Reason Presence of Precipitate: medication was crystallizing and particles floating in the bottle

Rising Pharma Holding, Inc. NDC 64980-504-48 D-0724-2026
Class I · High risk Ongoing

Cetirizine Hydrochloride Tablets USP 5 mg

Reason Cross Contamination with Other Products: Customer complaints for appearance of discolored tablets and red dots observed on Cetirizine Hydrochloride Tablets USP 5 mg. Determined to be Ranitidine.

JB Chemicals and Pharmaceuticals Ltd NDC 16571-401-10 D-0732-2026